These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 6577943

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Detection of 1-beta-D-arabinofuranosylcytosine incorporation into DNA in vivo.
    Spriggs D, Robbins G, Ohno Y, Kufe D.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6532-6. PubMed ID: 3479246
    [Abstract] [Full Text] [Related]

  • 43. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 15; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 44. Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole.
    Sato A, Montgomery JA, Cory JG.
    Cancer Res; 1984 Aug 15; 44(8):3286-90. PubMed ID: 6611198
    [Abstract] [Full Text] [Related]

  • 45. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
    Kees UR, Ford J, Dawson VM, Piall E, Aherne GW.
    Cancer Res; 1989 Jun 01; 49(11):3015-9. PubMed ID: 2720661
    [Abstract] [Full Text] [Related]

  • 46. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.
    Grant S, Turner A, Nelms P, Yanovich S.
    Leukemia; 1995 May 01; 9(5):808-14. PubMed ID: 7769843
    [Abstract] [Full Text] [Related]

  • 47. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity.
    Vadi H, Drewinko B.
    Cancer Res; 1986 Mar 01; 46(3):1105-9. PubMed ID: 3080232
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system.
    Kishi S, Goto N, Nakamura T, Ueda T.
    Cancer Res; 1999 Jun 01; 59(11):2629-34. PubMed ID: 10363985
    [Abstract] [Full Text] [Related]

  • 50. Cytotoxic effects of 1-beta-D-arabinofuranosylcytosine and 6-thioguanine in vitro on granulocytic progenitor cells.
    Greenberg PL, VanKersen I, Mosny S.
    Cancer Res; 1976 Dec 01; 36(12):4412-7. PubMed ID: 1069606
    [Abstract] [Full Text] [Related]

  • 51. [The effects of histamine H2 receptor agonist, antagonist and antineoplastic agent on the in vitro growth of PB CFU-GM from normal individuals and HL-60 leukemia cells].
    He Q, Xu YH.
    Yao Xue Xue Bao; 1996 Dec 01; 31(5):340-5. PubMed ID: 9275711
    [Abstract] [Full Text] [Related]

  • 52. Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells.
    Gustavsson A, Olofsson T.
    Cancer Res; 1984 Oct 01; 44(10):4648-52. PubMed ID: 6590116
    [Abstract] [Full Text] [Related]

  • 53. Effect of uridine on response of 5-azacytidine-resistant human leukemic cells to inhibitors of de novo pyrimidine synthesis.
    Grant S, Bhalla K, Gleyzer M.
    Cancer Res; 1984 Dec 01; 44(12 Pt 1):5505-10. PubMed ID: 6208998
    [Abstract] [Full Text] [Related]

  • 54. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
    Colly LP, Peters WG, Willemze R.
    Cancer Res; 1986 Aug 01; 46(8):3825-7. PubMed ID: 3460691
    [Abstract] [Full Text] [Related]

  • 55. Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic human myeloid progenitor cells.
    Grant S, Bhalla K, Gleyzer M.
    Leuk Res; 1986 Aug 01; 10(9):1139-46. PubMed ID: 2429121
    [Abstract] [Full Text] [Related]

  • 56. Enhancement of the DNA breakage and cytotoxic effects of intercalating agents by treatment with sublethal doses of 1-beta-D-arabinofuranosylcytosine or hydroxyurea in L1210 cells.
    Minford J, Kerrigan D, Nichols M, Shackney S, Zwelling LA.
    Cancer Res; 1984 Dec 01; 44(12 Pt 1):5583-93. PubMed ID: 6208999
    [Abstract] [Full Text] [Related]

  • 57. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb 01; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 58. Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells.
    Bhalla K, Swerdlow P, Grant S.
    Blood; 1991 Dec 01; 78(11):2937-44. PubMed ID: 1954383
    [Abstract] [Full Text] [Related]

  • 59. Differential effect of interleukin 3 on the metabolism of high-dose cytosine arabinoside in normal versus leukemic human bone marrow cells.
    Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Safah H, Graham G.
    Exp Hematol; 1991 Aug 01; 19(7):669-73. PubMed ID: 1893953
    [Abstract] [Full Text] [Related]

  • 60. In vitro biochemical and cytotoxicity studies with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine in combination.
    Momparler RL, Goodman J, Karon M.
    Cancer Res; 1975 Oct 01; 35(10):2853-7. PubMed ID: 50882
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.